A61K31/60

Compositions and Methods for Treating Cardiovascular Diseases

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.

Topical roflumilast formulation having antifungal properties

The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.

Topical roflumilast formulation having antifungal properties

The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.

Topical roflumilast formulation having antifungal properties

The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.

HEALTH CARE
20180008618 · 2018-01-11 ·

The treatment of Type 2 diabetes involving the use of a regimen comprising: (A) one or more glucose-lowering drugs (G-LDs) which function to lower the amount of glucose in the blood, preferably glyburide and metformin; (B) at least one non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of (1) magnesium salicylate tetrahydrate (hereafter “Mg salicylate”); (2) naproxen; and (3) ibuprofen; and (C) acetaminophen. Also, a regimen for use in deterring the development in an individual of a cardiovascular disease or of Alzheimer's and/or for treating individuals who are affected with such diseases, the regimen comprising aforementioned ingredients (B) and (C) above.

HEALTH CARE
20180008618 · 2018-01-11 ·

The treatment of Type 2 diabetes involving the use of a regimen comprising: (A) one or more glucose-lowering drugs (G-LDs) which function to lower the amount of glucose in the blood, preferably glyburide and metformin; (B) at least one non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of (1) magnesium salicylate tetrahydrate (hereafter “Mg salicylate”); (2) naproxen; and (3) ibuprofen; and (C) acetaminophen. Also, a regimen for use in deterring the development in an individual of a cardiovascular disease or of Alzheimer's and/or for treating individuals who are affected with such diseases, the regimen comprising aforementioned ingredients (B) and (C) above.

HEALTH CARE
20180008618 · 2018-01-11 ·

The treatment of Type 2 diabetes involving the use of a regimen comprising: (A) one or more glucose-lowering drugs (G-LDs) which function to lower the amount of glucose in the blood, preferably glyburide and metformin; (B) at least one non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of (1) magnesium salicylate tetrahydrate (hereafter “Mg salicylate”); (2) naproxen; and (3) ibuprofen; and (C) acetaminophen. Also, a regimen for use in deterring the development in an individual of a cardiovascular disease or of Alzheimer's and/or for treating individuals who are affected with such diseases, the regimen comprising aforementioned ingredients (B) and (C) above.

Cosmetic compositions and methods
11707427 · 2023-07-25 · ·

The current disclosure relates to a combination of ingredients including Plumeria alba (Frangipani) flower extract and salicylic acid. The composition can further contain hydroxyacetophenone, titanium dioxide, and/or carrageenan. This combination of components has been shown to be useful as a cleansing composition that is effective for reducing sebum, increasing clarity of the skin, and for improving the appearance of the skin by reducing shine and pore size. This combination of components has further been shown to be useful for reducing irritation and inflammation in the skin.

Cosmetic compositions and methods
11707427 · 2023-07-25 · ·

The current disclosure relates to a combination of ingredients including Plumeria alba (Frangipani) flower extract and salicylic acid. The composition can further contain hydroxyacetophenone, titanium dioxide, and/or carrageenan. This combination of components has been shown to be useful as a cleansing composition that is effective for reducing sebum, increasing clarity of the skin, and for improving the appearance of the skin by reducing shine and pore size. This combination of components has further been shown to be useful for reducing irritation and inflammation in the skin.

Cosmetic compositions and methods
11707427 · 2023-07-25 · ·

The current disclosure relates to a combination of ingredients including Plumeria alba (Frangipani) flower extract and salicylic acid. The composition can further contain hydroxyacetophenone, titanium dioxide, and/or carrageenan. This combination of components has been shown to be useful as a cleansing composition that is effective for reducing sebum, increasing clarity of the skin, and for improving the appearance of the skin by reducing shine and pore size. This combination of components has further been shown to be useful for reducing irritation and inflammation in the skin.